Piper Sandler Downgrades LENZ Therapeutics to Neutral, Lowers Price Target to $12

Benzinga Newsdesk www.benzinga.com Negative 88.9%

Neg 88.9% Neu 0% Pos 0%

Piper Sandler analyst Biren Amin downgrades LENZ Therapeutics (NASDAQ:LENZ) from Overweight to Neutral and lowers the price target from $39 to $12.